BACKGROUND: Survival advantage following trans-arterial chemoembolization (TACE) is variable in patients with hepatocellular carcinoma (HCC). We combined pre-TACE radiologic features to derive a novel prognostic signature in HCC. METHODS: A multi-institutional dataset of 98 patients was generated from two retrospective cohorts from United Kingdom (65%) and Italy (36%). The prognostic impact of a number baseline imaging parameters was assessed and factors significant on univariate analysis were combined to create a novel radiologic signature on multivariable analyses predictive of overall survival (OS) following TACE. RESULTS: Median OS was 15.4 months. Tumour size > 7 cm (p 7 cm, ITN and AEN identified patients with poor prognosis (p < 0.0...
This study sought to identify factors that are predictive of a therapeutic response to hepatic arter...
Background & Aims: Although potentially very useful in optimizing patient selection and follow-up, t...
BACKGROUND & AIMS: Transcatheter arterial chemoembolization (TACE) currently is used as a pallia...
Abstract Background Survival advantage following trans-arterial chemoembolization (TACE) is variable...
PURPOSE:Transarterial chemoembolization (TACE) is an established treatment for intermediate stage he...
The heterogeneity of intermediate-stage hepatocellular carcinoma (HCC) and the widespread use of tra...
AbstractBackgroundRadiographical features associated with a favourable response to trans-arterial ch...
Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treate...
AbstractBackground & AimsThe Pre‐TACE‐Predict model was devised to assess prognosis of patients trea...
Abstract We aimed to identify hepatocellular carcinoma (HCC) patients who will respond to repetitive...
This study attempted to validate the prognostic performance of the proposed Pre- and Post-TACE (tran...
AbstractBackgroundDespite advances in the treatment of hepatocellular carcinoma (HCC), a great propo...
AbstractBackgroundTransarterial chemoembolization (TACE) is the most common treatment for patients w...
BACKGROUND: The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial ...
Background& Aims: Time to progression (TTP) and progression-free survival (PFS) are commonly use...
This study sought to identify factors that are predictive of a therapeutic response to hepatic arter...
Background & Aims: Although potentially very useful in optimizing patient selection and follow-up, t...
BACKGROUND & AIMS: Transcatheter arterial chemoembolization (TACE) currently is used as a pallia...
Abstract Background Survival advantage following trans-arterial chemoembolization (TACE) is variable...
PURPOSE:Transarterial chemoembolization (TACE) is an established treatment for intermediate stage he...
The heterogeneity of intermediate-stage hepatocellular carcinoma (HCC) and the widespread use of tra...
AbstractBackgroundRadiographical features associated with a favourable response to trans-arterial ch...
Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treate...
AbstractBackground & AimsThe Pre‐TACE‐Predict model was devised to assess prognosis of patients trea...
Abstract We aimed to identify hepatocellular carcinoma (HCC) patients who will respond to repetitive...
This study attempted to validate the prognostic performance of the proposed Pre- and Post-TACE (tran...
AbstractBackgroundDespite advances in the treatment of hepatocellular carcinoma (HCC), a great propo...
AbstractBackgroundTransarterial chemoembolization (TACE) is the most common treatment for patients w...
BACKGROUND: The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial ...
Background& Aims: Time to progression (TTP) and progression-free survival (PFS) are commonly use...
This study sought to identify factors that are predictive of a therapeutic response to hepatic arter...
Background & Aims: Although potentially very useful in optimizing patient selection and follow-up, t...
BACKGROUND & AIMS: Transcatheter arterial chemoembolization (TACE) currently is used as a pallia...